Description

Indication & Scope

Vericiguat is for adult patients with symptomatic chronic heart failure with reduced ejection fraction who have experienced a recent heart failure exacerbation, belonging to the therapeutic field of cardiovascular diseases, to lower risks of cardiovascular death and heart failure hospitalization.

Drug class
Oral soluble guanylate cyclase (sGC) stimulator, novel cardiovascular anti-heart failure agent.
Mechanism
It directly stimulates soluble guanylate cyclase independent of nitric oxide, elevates intracellular cGMP levels to dilate blood vessels, reduce cardiac preload and afterload, relieve myocardial wall stress and inhibit ventricular remodeling, improving cardiac function without relying on endogenous NO pathway.
Clinical use
Once daily oral dose starting at 2.5 mg, titrated to 10 mg per tolerance. The VICTORIA Phase III trial proved it cuts cardiovascular death/HF hospitalization risks for decompensated HFrEF patients with steady long-term safety, used as add-on to standard HF treatments.

Specification

Generic Name	Vericiguat Tablets
Brand Name	Verquvo
Ingredient	Active ingredient: Vericiguat; Excipients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, macrogol
Dosage Form	Oral film-coated tablet, 2.5mg
Package	Carton box containing 14 tablets
Conditions Treated	Treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction after recent heart failure worsening, to reduce the risk of cardiovascular death and heart failure hospitalization
Taboos	Hypersensitivity to vericiguat or any excipients; Pregnancy and breastfeeding women
Place of origin	Germany
Prescription type	Prescription-only medicine (Rx)
Storage Conditions	Store below 30°C, tightly closed, away from moisture and direct sunlight
Manufacturer	Bayer AG, Manufacturing site: Bayer Pharma AG, Berlin, Germany
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	HJ20210046
Date of Revision	2024
Shelf Life	24 months

How to use ?

Recommended Dose: Start with 2.5 mg once daily. After 2 weeks, increase to 5 mg once daily if tolerated; further titrate to the target dose of 10 mg once daily after another 2 weeks based on blood pressure and tolerance. Do not exceed 10 mg daily.

Time：Take orally at the same time every day, with or without food.

Instructions for use: Swallow whole tablet with water; do not split, crush or chew. Take missed dose promptly, no double dose. Stop use and see doctor for lasting symptomatic hypotension.

Interaction: Strong PDE5 inhibitors are forbidden due to severe hypotension risk. Combined antihypertensives may lower blood pressure excessively and require close monitoring; no notable CYP450 interactions exist.

Side effects: Common side effects have Hypotension, anemia, dizziness.Rare serious adverse reactions have Syncope, orthostatic hypotension, severe symptomatic low blood pressure, gastrointestinal discomfort.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support